This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matthews, J. E. Search for Related Content PubMed PubMed Citation Articles by Matthews, J. E. Related Collections Diabetes and Insulin

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

GlaxoSmithKline (J.E.M., R.L.D., R.J.H., M.A.B.), Research Triangle Park, North Carolina 27709; GlaxoSmithKline (M.W.S., E.H.D.B., M.C.H.), King of Prussia, Pennsylvania 19406; and Pharmasset, Inc. (S.E.W.), Durham, North Carolina 22713

Address all correspondence and requests for reprints to: Murray W. Stewart, D.M., F.R.C.P., Alternative Development Program, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406–0939. E-mail: murray.w.stewart{at}gsk.com.

Context: Native glucagon-like peptide-1 increases insulin secretion, decreases glucagon secretion, and reduces appetite but is rapidly inactivated by dipeptidyl peptidase-4. Albiglutide is a novel dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin designed to have sustained efficacy in vivo.

Objectives: The objectives were to investigate pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide in type 2 diabetes subjects.

Methods: In a single-blind dose-escalation study, 54 subjects were randomized to receive placebo or 9-, 16-, or 32-mg albiglutide on d 1 and 8. In a complementary study, 46 subjects were randomized to a single dose (16 or 64 mg) of albiglutide to the arm, leg, or abdomen.

Results: Significant dose-dependent reductions in 24-h mean weighted glucose [area under the curve_{(0–24 h)}] were observed, with placebo-adjusted least squares means difference values in the 32-mg cohort of –34.8 and –56.4 mg/dl [95% confidence interval (–54.1, –15.5) and (–82.2, –30.5)] for d 2 and 9, respectively. Placebo-adjusted fasting plasma glucose decreased by –26.7 and –50.7 mg/dl [95% confidence interval (–46.3, –7.06) and (–75.4, –26.0)] on d 2 and 9, respectively. Postprandial glucose was also reduced. No hypoglycemic episodes were detected in the albiglutide cohorts. The frequency and severity of the most common adverse events, headache and nausea, were comparable with placebo controls. Albiglutide half-life ranged between 6 and 7 d. The pharmacokinetics or pharmacodynamic of albiglutide was unaffected by injection site.

Conclusions: Albiglutide improved fasting plasma glucose and postprandial glucose with a favorable safety profile in subjects with type 2 diabetes. Albiglutide’s long half-life may allow for once-weekly or less frequent dosing.

This article has been cited by other articles:

				T. L. Levien and D. E. Baker New Drugs in Development for the Treatment of Diabetes Diabetes Spectr, April 1, 2009; 22(2): 92 - 106. [Abstract] [Full Text] [PDF]